Regeneron Begins Clinical Trials of Antibody Cocktail Treatment for CCP Virus

Reporter

6/12/2020|Updated: 6/12/2020

Biopharmaceutical company Regeneron has started clinical testing of the antibody cocktail for the prevention and treatment of the CCP virus and the drug could be available for emergency use in a few months.

“We are particularly excited to begin studies of REGN-COV2, which is a novel antibody cocktail targeted specifically against SARS-CoV-2,” said trial investigator Dr. Suraj Saggar in a statement.

Venus Upadhayaya

Reporter

Venus Upadhayaya reports on India, China, and the Global South. Her traditional area of expertise is in Indian and South Asian geopolitics. Community media, sustainable development, and leadership remain her other areas of interest.

Author’s Selected Articles

China’s Footprint Is Clear in Kashmir Crisis, Analysts Say

Taiwan’s Tougher China Stance Should Bolster Support From Other Nations: Experts

On the Brink of a Multipolar World, India’s Grand Strategy Is Largely Defined by China, Analysts Say

CCP–Cook Islands Deal Raises Concerns for New Zealand, US, Australia